EZZ moves closer to breakthrough with world-first study into the health care product, NMN

Australian health and wellness company, EZZ Life Science Holdings, is advancing scientific research of popular health care product Nicotinamide mononucleotide (NMN), tapping into a growing trend for modern consumer products to tackle age-related wellbeing issues. EZZ is building scientific data with a leading university to show that being able to improve health.

EZZ has teamed up with Professor Jun Lu, the Chief founder of Auckland University of Technology (AUT)’s Biomedical Research Laboratory, to collect and analyse consumer datasets that may demonstrate the effectiveness of NMN in turning back the hands of time with health care products. Aging brings high risk factors associated with many chronic diseases, although with improved research into NMN, health care products are gaining increasing acceptance among consumers to alleviate these risks.

NMN, which is involved in generating Nicotinamide adenine dinucleotide (NAD+), a molecule that supplies energy to cells and activates a protein, sirtuin, to regulate cellular health, has grown in popularity, particularly among the elderly population, for its therapeutic effects in promoting health and ameliorating various complications and diseases.

A world-first literature review published by the highly rated Journal of Advanced Research (JARE, impact factor 10.48) revealed breakthroughs in scientific knowledge, allowing for a much clearer understanding of why these NMN consumer items are so widely sought after around the world. EZZ and AUT are collaborating to build on progress in this field, addressing the growing requirement by consumers for leading edge health care products with the support of scientific evidence.

The JARE publication notes that NAD+ levels in the body deplete with aging. This depletion is associated with downregulation of energy production in mitochondria, oxidative stress, DNA damage, cognitive impairment, and inflammatory conditions. However, use of NMN, as the precursor of NAD+, is aimed at slowing down this process by elevating NAD+ levels in the cells.

Professor Lu commented, “EZZ is very encouraged by a number of in vivo studies which have yielded positive early data showing NMN’s potential to treat various age-induced complications. The JARE review shows that knowledge in this exciting new field is advancing and reinforces the importance of continuing to develop the understanding of NMN through further clinical studies.”

“In partnership with EZZ, EZZ is boosting its customer feedback tracking database to expand its research into therapeutic health care effects of NMN use. EZZ is planning to capture longitudinal customer feedback which will help EZZ staff to understand the real-world outcomes that people are achieving through use of NMN-based products. EZZ will also implement a statistical model to determine the efficacy of NMN in health care.”

EZZ CEO Fernando Rodriguez added, “EZZ is delighted to welcome this world-first literature review to complement its existing knowledge of NMN. EZZ is committed to advancing NMN research and through the partnership with Auckland University of Technology EZZ is confident of significantly expanding its level of scientific knowledge about the long-term safety and clinical efficacy of using NMN in health care products.”

Media Contact
Company Name: EZZ Pty Ltd
Contact Person: Andy
Email: Send Email
Country: Australia
Website: http://ozezz.com.au